Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer
- 1 February 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in DNA and Cell Biology
- Vol. 42 (2), 73-81
- https://doi.org/10.1089/dna.2022.0578
Abstract
Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) is an aggressive malignancy with a high recurrence rate and reduced overall survival. Immune checkpoint inhibition (ICI) has shown modest results in this subgroup, highlighting the need for improved targeted therapeutic options. Notch is a defining feature of TNBC and drives the expression of interleukin-1 beta (IL1β) and C-C motif chemokine ligand 2 (CCL2). These cytokines are involved in the recruitment of tumor-associated macrophages (TAMs) to the tumor, resulting in immune evasion and tumor progression. Targeting Notch, IL1β or CCL2 may reduce TAM recruitment and resistance to ICI, illuminating the potential of combination immunotherapy in TNBC.Keywords
This publication has 110 references indexed in Scilit:
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytesNature, 1992